Bone Biologics Announces First Two Patients Treated In Pilot Clinical Study Of NB1 Bone Graft Device; NB1 Combines NELL-1 Protein With Demineralized Bone Matrix For Enhanced Bone Regeneration
Portfolio Pulse from Benzinga Newsdesk
Bone Biologics has announced the treatment of the first two patients in a pilot clinical study of its NB1 bone graft device, which combines the NELL-1 protein with demineralized bone matrix to enhance bone regeneration.
June 20, 2024 | 12:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bone Biologics has treated the first two patients in a pilot clinical study of its NB1 bone graft device, which aims to enhance bone regeneration by combining the NELL-1 protein with demineralized bone matrix.
The initiation of a pilot clinical study and the treatment of the first two patients is a significant milestone for Bone Biologics. This development could lead to positive investor sentiment and potential stock price appreciation as it demonstrates progress in the company's product pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100